Shuttle Pharmaceuticals Receives Nasdaq Notice for 10‑Q Delinquency

What Happened

• Shuttle Pharmaceuticals Holdings, Inc. announced on August 28, 2026 that it received a notification from Nasdaq’s Listing Qualifications Department saying the company no longer meets Nasdaq Listing Rule 5250(c)(1) because it has not timely filed its Quarterly Report on Form 10‑Q for the period ended June 30, 2026.
• The company issued a related press release (Exhibit 99.1) and said it is working to complete the Form 10‑Q as soon as practicable.

Key Details

• Notice received: August 28, 2026.
• Company has 60 calendar days (until October 27, 2026) to submit a plan to Nasdaq to regain compliance.
• If Nasdaq accepts the plan, it may grant an exception allowing up to 180 days from the Form 10‑Q due date (until February 22, 2027) to regain compliance.
• Nasdaq will broadcast a noncompliance indicator over its market data network; there is no immediate delisting or trading suspension. If the company fails to regain compliance, its common stock may be delisted. The company may appeal any Nasdaq decision to a hearings panel.
• The filing notes key factors affecting timing: the independent registered public accounting firm’s completion of required review procedures and the company’s ability to file the Form 10‑Q.

Why It Matters

• For investors, the notice signals regulatory risk: failure to regain compliance could lead to delisting, which would reduce liquidity and could affect market value and investor access to the shares.
• The situation depends on completing the accounting review and filing the outstanding Form 10‑Q or obtaining an extension from Nasdaq; the company has indicated it intends to file as soon as practicable but there is no assurance Nasdaq will accept its plan or that compliance will be restored.